These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 13151175)

  • 1. The vasoconstrictor factor of platelets.
    BRACCO M; CURTI PC
    Experientia; 1954 Feb; 10(2):71-2. PubMed ID: 13151175
    [No Abstract]   [Full Text] [Related]  

  • 2. [Method of determination of 5-hydroxytryptamine (platelet vasoconstrictor factor) in the blood].
    BRACCO M; CURTI PC; GIULIANO V
    Farmaco Sci; 1955; 10(9):595-615. PubMed ID: 13285535
    [No Abstract]   [Full Text] [Related]  

  • 3. [Observations on the hemodynamic effect of the platelet vasoconstrictor factor. Behavior of the venous pressure in patients with mitral stenosis].
    ANDREONE A; CIANCAGLINI L
    Minerva Cardioangiol; 1960 May; 8():215-8. PubMed ID: 13793577
    [No Abstract]   [Full Text] [Related]  

  • 4. [Studies on the nature of vasoconstrictor factor of blood platelets].
    BRACCO M; CURTI PC
    Haematologica; 1953; 37(7):721-36. PubMed ID: 13128520
    [No Abstract]   [Full Text] [Related]  

  • 5. The response of cortical vessels to serotonin in experimental cerebral infarction.
    Bell WH; Sundt TM; Nofzinger JD
    J Neurosurg; 1967 Feb; 26(2):203-12. PubMed ID: 4959975
    [No Abstract]   [Full Text] [Related]  

  • 6. Relationship of sonically disrupted platelets to serum vasoconstrictor activity.
    COLE JW; LIVINGSTON H; LOUGHRY CW; HOLDEN WD
    Surgery; 1953 Sep; 34(3):482-90. PubMed ID: 13090038
    [No Abstract]   [Full Text] [Related]  

  • 7. [Identification of the vasoconstrictor factor of blood platelets with 5-hydroxytryptamine].
    BRACCO M; CURTI PC
    Quad Clin Ostet Ginecol; 1954; 9():7-10. PubMed ID: 13194821
    [No Abstract]   [Full Text] [Related]  

  • 8. Observations on the part played by the vasoconstrictor substance of blood platelets in the mechanism of vascular spasm.
    REID G
    Med J Aust; 1947 Aug; 2(5):139-41. PubMed ID: 20259898
    [No Abstract]   [Full Text] [Related]  

  • 9. Cerebral arterial spasm. 3. Partial purification and characterization of a spasmogenic substance in feline platelets.
    Kapp J; Mahaley MS; Odom GL
    J Neurosurg; 1968 Oct; 29(4):350-6. PubMed ID: 4301730
    [No Abstract]   [Full Text] [Related]  

  • 10. Comparison of vasodilator effects on human middle cerebral artery constriction induced by vasoconstrictors or activated platelets.
    Akopov SE; Balayan BG; Gabrielian ES
    Methods Find Exp Clin Pharmacol; 1992; 14(6):437-9. PubMed ID: 1469952
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Role of serotonin in the pathogenesis of cerebral circulatory disorders (review)].
    Makarov AIu; Pomnikov VG
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1982; 82(8):118-26. PubMed ID: 6753426
    [No Abstract]   [Full Text] [Related]  

  • 12. Dominant contribution of 5-hydroxytryptamine over thromboxane A2 in contractile response of rabbit isolated aortic preparation to thrombin activated platelets.
    Nakanishi H; Matsuoka I; Ono T; Nakahata N
    Res Commun Mol Pathol Pharmacol; 1995 Nov; 90(2):255-67. PubMed ID: 8747793
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serotonin and preactivated platelets in essential hypertension.
    Bühler FR; Amstein R; Fetkovska N
    J Cardiovasc Pharmacol; 1987; 10 Suppl 3():S32-4. PubMed ID: 2446066
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of lithium on adrenergic function in man.
    Fann WE; Davis JM; Janowsky DS; Cavanaugh JH; Kaufmann JS; Griffith JD; Oates JA
    Clin Pharmacol Ther; 1972; 13(1):71-7. PubMed ID: 5008194
    [No Abstract]   [Full Text] [Related]  

  • 15. Physiological actions of the partially purified serum vasoconstrictor (serotonin).
    REID G; RAND M
    Aust J Exp Biol Med Sci; 1951 Nov; 29(6):401-15. PubMed ID: 14904317
    [No Abstract]   [Full Text] [Related]  

  • 16. Inhibition by acetamidophenol of the production of prostaglandin-like material from blood platelets in vitro in relation to some in vivo actions.
    Vargaftig BB; Hai ND
    Eur J Pharmacol; 1973 Dec; 24(3):283-8. PubMed ID: 4148841
    [No Abstract]   [Full Text] [Related]  

  • 17. Age and the platelet serotonin vasoconstrictor axis in essential hypertension.
    Amstein R; Fetkovska N; Lüscher TF; Kiowski W; Bühler FR
    J Cardiovasc Pharmacol; 1988; 11 Suppl 1():S35-40. PubMed ID: 2459512
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Release of a neutrophil-derived vasoconstrictor agent which augments platelet-induced contractions of blood vessels in vitro.
    Sessa WC; Mullane KM
    Br J Pharmacol; 1990 Mar; 99(3):553-9. PubMed ID: 2110018
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interaction of human platelets and leukocytes in modulation of vascular tone.
    Kaul S; Waack BJ; Padgett RC; Brooks RM; Heistad DD
    Am J Physiol; 1994 May; 266(5 Pt 2):H1706-14. PubMed ID: 8203570
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neurogenic inhibitory action through platelets of platelet activating factor (PAF) on vasoconstrictive responsiveness to pressor agents.
    Michibayashi T
    Adv Exp Med Biol; 1997; 433():243-7. PubMed ID: 9561145
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.